Incyte Genomics Inc (INCY)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Incyte Genomics Inc (INCY)
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Key Insights
Critical company metrics and information
Share Price
$71.94Market Cap
$13.86 BillionTotal Outstanding Shares
192.65 Million SharesTotal Employees
2,524Dividend
No dividendIPO Date
November 3, 1993SIC Description
Services-commercial Physical & Biological ResearchHomepage
https://www.incyte.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $24.48 Million |
Net Cash Flow From Investing Activities | $24.48 Million |
Net Cash Flow From Operating Activities, Continuing | $101.85 Million |
Net Cash Flow From Financing Activities, Continuing | $-2.04 Billion |
Net Cash Flow | $-1.92 Billion |
Exchange Gains/Losses | $-7.84 Million |
Net Cash Flow, Continuing | $-1.92 Billion |
Net Cash Flow From Financing Activities | $-2.04 Billion |
Net Cash Flow From Operating Activities | $101.85 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Operating Expenses | $40.78 Million |
Diluted Earnings Per Share | $0.09 |
Research and Development | $2.59 Billion |
Basic Earnings Per Share | $0.10 |
Basic Average Shares | $211.96 Million |
Diluted Average Shares | $211.94 Million |
Income/Loss From Continuing Operations After Tax | $32.48 Million |
Selling, General, and Administrative Expenses | $1.21 Billion |
Cost Of Revenue | $293.33 Million |
Revenues | $4.08 Billion |
Income/Loss From Continuing Operations Before Tax | $273.86 Million |
Costs And Expenses | $4.13 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $32.48 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Operating Income/Loss | $-52.88 Million |
Operating Expenses | $3.84 Billion |
Income Tax Expense/Benefit | $241.38 Million |
Gross Profit | $3.78 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Benefits Costs and Expenses | $3.80 Billion |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss | $32.48 Million |
Net Income/Loss Attributable To Parent | $32.48 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Assets | $2.20 Billion |
Accounts Payable | $178.71 Million |
Liabilities | $1.84 Billion |
Other Current Assets | $2.74 Billion |
Noncurrent Liabilities | $339.56 Million |
Wages | $150.72 Million |
Current Liabilities | $1.50 Billion |
Assets | $5.01 Billion |
Liabilities And Equity | $5.01 Billion |
Other Non-current Assets | $1.43 Billion |
Inventory | $70.44 Million |
Fixed Assets | $773.10 Million |
Equity Attributable To Parent | $3.17 Billion |
Other Current Liabilities | $1.17 Billion |
Equity | $3.17 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Assets | $2.81 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.